Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy

Table 7 Univariate and multivariate Cox regression analysis of factors associated with recurrence-free survival

Cluster	PSM before				PSM after
	Univariate		Multifactor		Univariate		Multifactor
	P value	HR	95%CI	P value	P value	HR	95%CI	P value
Receiving adjuvant therapy (yes vs no)	0.042	0.717	0.521-0.988	0.01	0.031	0.659	0.450-0.964	0.005
diabetes (yes vs no)	0.758	0.94	0.633-1.395		0.315	0.761	0.447-1.295
ECOG score (0 vs 1)	0.891	0.98	0.740-1.299		0.9	0.975	0.653-1.454
Age (≤ 60 vs > 60)	0.401	0.893	0.685-1.164		0.632	0.91	0.618-1.339
Sex (male vs female)	0.681	0.914	0.594-1.405		0.721	1.12	0.600-2.090
HBsAg (positive vs negative)	0.603	0.928	0.700-1.230		0.077	0.679	0.441-1.043	0.13
HBsAb (positive vs negative)	0.662	1.06	0.815-1.379		0.949	1.013	0.686-1.495
AST, U/L (≤ 37 vs > 37)	0.005	0.686	0.527-0.893	0.23	0.035	0.655	0.443-0.970	0.13
ALT, U/L (≤ 40 vs > 40)	0.012	0.719	0.556-0.930	0.416	0.033	0.665	0.456-0.968	0.489
HCV DNA (positive vs negative)	0.274	0.723	0.404-1.293		0.697	0.757	0.187-3.072
HBV DNA, IU/mL (≤ 2000 vs > 2000)	0.677	1.057	0.814-1.373		0.225	0.792	0.543-1.154
AFP, μg/L (≤ 400 vs > 400)	0.058	1.358	0.990-1.862	0.026	0.206	1.309	0.863-1.985
ALBI score (1 vs 2/3)	0.021	0.714	0.537-0.950	0.119	0.077	0.668	0.427-1.045	0.155
Hydroperitoneum (yes vs no)	0.43	1.12	0.846-1.482		0.509	1.139	0.774-1.678
Child-Pugh grade (A vs B)	0.675	0.902	0.558-1.460		0.76	1.127	0.523-2.426
Number of tumors (1 vs ≥ 2)	0.208	0.833	0.627-1.107		0.094	0.692	0.450-1.065	0.07
Maximum tumor diameter (mm)	0.001	1.005	1.002-1.009	0.053	0.01	1.006	1.002-1.011	0.039
Cirrhosis (yes vs no)	0.588	1.075	0.828-1.395		0.21	1.276	0.872-1.867
PVTT (yes vs no)	0.156	0.779	0.552-1.100		0.518	1.46	0.463-4.607
HVTT (yes vs no)	0.077	0.614	0.358-1.055	0.126	0.615	0.822	0.382-1.768
Satellite node (yes vs no)	0.4	1.229	0.760-1.989		0.702	1.136	0.592-2.177
Peritoneal invasion or absence (yes vs no)	0.587	0.925	0.697-1.227		0.487	0.866	0.576-1.300
Tumor rupture (yes vs no)	0.885	1.029	0.697-1.519		0.894	0.966	0.583-1.602
CNLC staging (Ⅲ vs I/II)	0.132	0.769	0.547-1.082		0.323	1.354	0.743-2.469
Edmonson tumor grade (Ⅲ-IV vs I-II)	0.709	1.054	0.798-1.393		0.623	0.91	0.625-1.325
MVI (M1/M2 vs M0)	0.075	0.79	0.610-1.024	0.193	0.448	0.863	0.590-1.263
High recurrence risk factors (multiple vs single)	0.038	0.736	0.551-0.984	0.32	0.674	0.915	0.606-1.383
Surgical methods (open vs laparoscopy/robot)	0.469	0.896	0.666-1.206		0.337	0.81	0.527-1.245
Anatomic resection (yes vs no)	0.585	1.078	0.824-1.410		0.932	1.017	0.698-1.481
Tumor margin (< 1 cm vs ≥ 1 cm)	0.786	0.963	0.733-1.265		0.764	1.062	0.717-1.572
Blocking the hepatic portal (yes vs no)	0.925	1.013	0.779-1.317		0.63	0.911	0.625-1.330
Transfusion (yes vs no)	0.57	0.898	0.618-1.304		0.367	1.295	0.738-2.273

ECOG: Eastern Cooperative Oncology Group; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin score; PVTT: Portal vein tumor thrombus; HVTT: Hepatic vein tumor thrombus; CNLC: China Liver Cancer; MVI: Microvascular invasion; PSM: Propensity score matching; HR: Hazard ratio; CI: Confidence interval.